AVAX Technologies Inc., of Kansas City, Mo., appointed Henry Schea director of quality systems.

BioForce Nanosciences Inc., of Ames, Iowa, appointed Gary Alianell president, CEO and a member of its board.

Biophage Pharma Inc., of Montreal, appointed Toney Ilenchuk vice president and chief development officer.

Cellzome AG, of Heidelberg, Germany, appointed George Casari vice president, informatics.

Chiron Corp., of Emeryville, Calif., named William Green president of its blood testing division.

Corgentech Inc., of Palo Alto, Calif., promoted Mauri Okamoto-Kearney to vice president of product development.

Cortex Pharmaceuticals Inc., of Irvine, Calif., added Arvid Carlsson as a consultant to its board.

Cortex Pharmaceuticals Inc., of Irvine, Calif., appointed Joann Data senior vice president, clinical development and regulatory affairs.

Cyclacel Ltd., of Dundee, Scotland, appointed Paul McBarron chief financial officer and a member of its board.

Deltagen Inc., of Redwood City, Calif., appointed David Beier to its board.

EngeneOS Inc., of Waltham, Mass., appointed Gordon Wong chief scientific officer.

Epicyte Pharmaceutical Inc., of San Diego, added Debra Robertson as director of intellectual property.

FibroGen Inc., of South San Francisco, added Pedro Urquilla as vice president, medical affairs.

Genaissance Pharmaceuticals Inc., of New Haven, Conn., promoted Gerald Vovis to executive vice president and Carol Reed to executive director of medical affairs.

Genetronics Biomedical Corp., of San Diego, appointed Arlene Forastiere, Gary Koch, Mark Leppert, Ian Thompson, Daniel Von Hoff and Robert Warren to its scientific advisory board.

Genmab A/S, of Copenhagen, Denmark, appointed Torben Lund-Hansen vice president, manufacturing.

GenVec Inc., of Gaithersburg, Md., elected Louis Sherwood to its board.

IBA GmbH, of Goettingen, Germany, named Lothar Germeroth CEO.

Indevus Pharmaceuticals Inc., of Lexington, Mass., appointed John Tucker vice president, sales and marketing.

InterMune Inc., of Brisbane, Calif., named Edgar Engleman chairman of its scientific advisory board.

Intradigm Corp., of Rockville, Md., named Paul Tolstoshev, Anton Wellstein, Bruce Trapnell, Dexi Liu, Richard Heller, Joel Jessee, Richard Gilbert, Hamid Ghandehari, James Mixson, Gerrit Storm and Victor Haodong Li to its scientific advisory board.

Kudos Pharmaceuticals Ltd., of Cambridge, UK, appointed David Dally chief financial officer.

Leerink Swann & Co., of Boston, added Richard Altschuler as managing director, head of global institutional sales; he also will serve as interim director of equity research.

Ligand Pharmaceuticals Inc., of San Diego, promoted Thomas Silberg to executive vice president and chief operating officer.

Nanogen Inc., of San Diego, appointed Robert Whalen to its board.

NeoGenomics Inc., of Naples, Fla., added Li-fang Liang to its scientific advisory board.

Neurotech SA, of Paris, appointed Bernard Chauvin as chairman of its board and interim CEO and promoted Bernard Davitian to executive vice president and chief operating officer.

Nucryst Pharmaceuticals Corp., of Wakefield, Mass., appointed Paul Schechter vice president, drug development and regulatory affairs and chief medical officer.

NuGEN Technologies Inc., of San Carlos, Calif., appointed Joe Gray to its advisory board.

Orrick, Herrington & Sutcliffe LLP, of Seattle, added Roger Tolbert to its corporate and technology practice.

Phylos Inc., of Lexington, Mass., appointed Edward Fritsch senior vice president of development and promoted Albert Collinson to senior vice president, business development.

PPD Inc., of Wilmington, N.C., promoted Richard Staub to vice president of global business development.

Screentec BV, of Leiden, the Netherlands, appointed Gerard Dijkstra CEO. Dijkstra is a former head of biotechnology at Solvay Pharmaceuticals Inc.

Sutter Hill Ventures, of Palo Alto, Calif., added Jeffrey Bird to its firm in the health care industry investment area.

U.S. Bancorp Piper Jaffray, of New York, added Timothy Coan in its equity capital markets division as a senior biotechnology research analyst.

UBS Warburg, of New York, added Meirav Chovav as senior biotechnology analyst.

Variagenics Inc., of Cambridge, Mass., promoted Joseph Mohr to president and chief business officer and named Richard Shea chief operating officer.

No Comments